The Campaign for Sustainable Drug Pricing introduced 12 policy proposals targeting drug companies, according to The Hill.
Here are five points:
1. The campaign is calling for transparency, asking drug manufacturers to release national pricing data as well as research and development costs.
2. Drug companies would also need to report more clinical trial data.
3. The drug manufacturers argue releasing this data would hurt them competitively.
4. The coalition also seeks to accelerate the generic drug approval process. It suggests offering more funding to the FDA to file through its drug application backlog.
5. The coalition does not include any drug company members.
